Despite recent progress in the fight against malaria, the emergence and spread of drug-resistant parasites remains a serious obstacle to the treatment of infections. We recently reported the development of a novel antimalarial drug that combines the 4-aminoquinoline pharmacophore of chloroquine with that of clotrimazole-based antimalarials. Here we describe the optimization of this class of hybrid drug through in depth structure-activity relationship studies. Antiplasmodial properties and mode of action were characterized in vitro and in vivo, and interactions with the parasite's 'chloroquine resistance transporter' were investigated in a Xenopus laevis oocyte expression system. These tests indicated that piperazine-derivatives 4b and 4d may be suitable for co-administration with chloroquine against chloroquine-resistant parasites. The potential for metabolism of the drugs by cytochrome P450 was determined in silico and the lead compounds were tested for toxicity and mutagenicity. A preliminary pharmacokinetic analysis undertaken in mice indicated that compound 4b has an optimal half-life.

Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials : Further Structure-Activity Relationships, in vivo Studies, and Preliminary Toxicity Profiling / S. Gemma, C. Camodeca, S. Sanna Coccone, B. P. Joshi, M. Bernetti, V. Moretti, S. Brogi, M. Bonache, L. Savini, D. Taramelli, N. Basilico, S. Parapini, M. Rottmann, R. Brun, S. Lamponi, S. Caccia, G. Guiso, R. Summer, R. Martin, S. Saponara, B. Gorelli, E. Novellino, G. Campiani, S. Butini. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 55:15(2012 Aug 09), pp. 6948-6967.

Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials : Further Structure-Activity Relationships, in vivo Studies, and Preliminary Toxicity Profiling

D. Taramelli;N. Basilico;S. Parapini;
2012

Abstract

Despite recent progress in the fight against malaria, the emergence and spread of drug-resistant parasites remains a serious obstacle to the treatment of infections. We recently reported the development of a novel antimalarial drug that combines the 4-aminoquinoline pharmacophore of chloroquine with that of clotrimazole-based antimalarials. Here we describe the optimization of this class of hybrid drug through in depth structure-activity relationship studies. Antiplasmodial properties and mode of action were characterized in vitro and in vivo, and interactions with the parasite's 'chloroquine resistance transporter' were investigated in a Xenopus laevis oocyte expression system. These tests indicated that piperazine-derivatives 4b and 4d may be suitable for co-administration with chloroquine against chloroquine-resistant parasites. The potential for metabolism of the drugs by cytochrome P450 was determined in silico and the lead compounds were tested for toxicity and mutagenicity. A preliminary pharmacokinetic analysis undertaken in mice indicated that compound 4b has an optimal half-life.
chloroquine-resistance transporter; plasmodium-falciparum; malaria parasites; drug-resistance; clinical pharmacokinetics; innovative pharmacophore; artemisinin resistance; clotrimazole scaffold; beta-hematin; force-field
Settore MED/04 - Patologia Generale
Settore MED/07 - Microbiologia e Microbiologia Clinica
9-ago-2012
Article (author)
File in questo prodotto:
File Dimensione Formato  
Gemma_Optimization of 4aminoquinolines_JMedChem 2012.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 3.18 MB
Formato Adobe PDF
3.18 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/201619
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 40
social impact